"The voice for cancer physicians and their patients in Massachusetts."
Randomized Phase 3 Clinical Trial of ADCETRIS Combination Met Key Secondary OS Endpoint, Demonstrating a 41% Reduction in Risk of Death vs. Standard of Care in Patients With Advanced Hodgkin Lymphoma. Read More.
Massachusetts Society of Clinical Oncologists ©2022
860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329 | Fax: 781.464.4896 | email: firstname.lastname@example.org